Pulse Biosciences to Present Innovative nsPFA Technology at AF Symposium 2025

Pulse Biosciences to Showcase Groundbreaking Technology at Upcoming AF Symposium

Pulse Biosciences, Inc., a Miami-based company, announces the upcoming presentation of its proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology at the 30th Annual AF Symposium 2025, scheduled for January 16-18 in Boston. This event is poised to spotlight significant advancements in the field of cardiac care, particularly through the live demonstration of the nsPFA 360° catheter, which is designed for efficient pulmonary vein isolation. The integration of this catheter with the Abbott Ensite X 3D Mapping System offers a modern approach to treating atrial fibrillation, a condition that affects millions worldwide.

At the symposium, attendees will gain insights into the latest clinical findings surrounding the nsPFA 360° Cardiac Catheter. Notably, on January 17, Dr. Vivek Reddy will share results from a feasibility study involving the first 30 patients who were treated using this innovative technology. The following day, Dr. Petr Neuzil will conduct a live case broadcast, demonstrating the catheter's capabilities in real-time. These presentations underscore Pulse Biosciences' commitment to clinical evidence and product development, as highlighted by Paul LaViolette, Co-Chairman of the Board. LaViolette emphasizes the progress the company has made since his tenure began last year, showcasing the rapid advancements in both the technology and the supporting clinical data.

Pulse Biosciences aims to initiate a pivotal U.S. Investigational Device Exemption (IDE) clinical study for the nsPFA 360° catheter in mid-2025. This study is expected to further validate the technology's effectiveness in non-thermally eliminating cardiac tissue while preserving adjacent structures. By advancing its nsPFA™ technology, Pulse Biosciences seeks not only to innovate healthcare solutions but also to enhance patient quality of life in the realm of cardiac health. The upcoming AF Symposium represents a critical platform for the company to engage with the clinical community and demonstrate its commitment to addressing significant healthcare challenges through cutting-edge technology.

In addition to the symposium, Pulse Biosciences continues to focus on its broader mission of transforming healthcare through its CellFX® nsPFA™ technology. This innovative approach has the potential to revolutionize the treatment of various conditions, including but not limited to atrial fibrillation. As the company prepares for its pivotal studies, it is positioned at the forefront of medical technology, striving to improve outcomes for patients and healthcare providers alike.